- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.07. | OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer | 212 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| 27.07. | OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 | 310 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 27.07. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.07. | OKYO Pharma Announces Purchase of Shares by Director | 285 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 23.07. | OKYO Pharma CEO purchases 15,000 shares at $1.54 each | 2 | Investing.com | ||
| 23.07. | OKYO Pharma Announces Purchase of Shares by Chief Executive Officer | 275 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 22.07. | OKYO Pharma Announces Purchase of Shares by Chairman | 290 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 22.07. | OKYO Pharma executive purchases 3,500 shares at $1.40 each | 2 | Investing.com | ||
| 22.07. | OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director | 276 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 22.07. | OKYO Pharma Announces Purchase of Shares by Chief Medical Officer | 278 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 21.07. | OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference | 357 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 21.07. | OKYO Pharma chairman increases stake with share purchase | 2 | Seeking Alpha | ||
| 21.07. | OKYO Pharma Announces Purchase of Shares by Chairman | 326 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 20.07. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.07. | OKYO Pharma files annual report, raises $25M for phase 3 trial | 2 | Investing.com | ||
| 20.07. | OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans | 283 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 20.07. | OKYO Pharma Ltd - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 13.07. | H.C. Wainwright cuts OKYO Pharma stock price target to $5 on share count | 3 | Investing.com | ||
| 08.07. | OKYO Pharma Says FDA Supports Advancement Of NEPTUNE Clinical Trial For Urcosimod | 2 | RTTNews | ||
| 08.07. | OKYO Pharma receives FDA feedback on phase 3 neuropathic pain trial | 2 | Investing.com |
1 2 3 4 Weiter >>
64 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 6,600 | -0,75 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 8,000 | -0,12 % | PALATIN TECHNOLOGIES INC - 8-K, Current Report | ||
| OCUGEN | 1,102 | -3,50 % | Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration | RMAT designation is intended to help expedite development of new regenerative medicines that have potential to treat serious medical conditions with significant unmet needThe designation could accelerate... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,273 | -1,44 % | NurExone Biologic Exosomen als möglicher Wendepunkt in der Glaukom-Therapie | ||
| IDEXX LABORATORIES | 509,00 | -0,24 % | IDEXX Labs Reports Higher Q2 Profit On Strong Revenue Growth; Lifts FY Earnings Outlook; Stock Up | WASHINGTON (dpa-AFX) - IDEXX Laboratories Inc. (IDXX), a developer of veterinary diagnostics, software and water testing solutions, reported higher second-quarter profit, driven by strong revenue... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,139 | -8,51 % | PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced the upcoming availability of SPRQ-Nx chemistry... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,634 | 0,00 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,408 | +5,15 % | Onco-Innovations Limited: Onco-Innovations Reports Progress Toward a Consistent and Scalable Polymer Manufacturing Process Supporting ONC010 | ||
| NOVOCURE | 14,080 | -0,18 % | Novocure Reports Second Quarter 2026 Financial Results | Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications
CE Mark received for Optune Paxfor the treatment of locally... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,450 | -0,67 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights | Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,768 | +2,67 % | BioXcel Therapeutics, Inc. - 8-K, Current Report | ||
| ROCKET PHARMACEUTICALS | 3,030 | +1,34 % | Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial | ||
| VOYAGER THERAPEUTICS | 2,676 | -1,25 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| PALISADE BIO | 2,125 | +2,66 % | Palisade Bio, Inc.: Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis | ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,162 | 0,00 % | Merck And ADAP Crisis Task Force Reach Agreement To Expand IDVYNSO Access |
OKYO PHARMA LIMITED gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -3,66 % bei einem Aktienkurs von 1,580 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.